

1 **Supporting Information**

2

3 **Synergizing Interventional Photothermal Therapy and**

4 **Immunotherapy with an Iron Oxide Nanoplatfrom for the**

5 **Treatment of Pancreatic Cancer**

6 Meng Wang<sup>1</sup>, Yong Li<sup>3</sup>, Miao Wang<sup>2</sup>, Kaili Liu<sup>4</sup>, Ashley R. Hoover<sup>4</sup>, Min Li<sup>5</sup>, Rheel  
7 A Towner<sup>6</sup>, Priyabrata Mukherjee<sup>7</sup>, Feifan Zhou<sup>2\*</sup>, Junle Qu<sup>1\*</sup>, and Wei R Chen<sup>4\*</sup>

8 <sup>1</sup> Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and  
9 Guangdong Province, College of Physics and Optoelectronic Engineering, Shenzhen  
10 University, Shenzhen, 518060, China.

11 <sup>2</sup> School of Biomedical Engineering, Hainan University, Haikou, 570228, China.

12 <sup>3</sup> Interventional Therapy Department, Tianjin Key Laboratory of Cancer Prevention and  
13 Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060,  
14 China.

15 <sup>4</sup> Stephenson School of Biomedical Engineering, University of Oklahoma, Norman,  
16 Oklahoma 73019, USA.

17 <sup>5</sup> Department of Medicine, Department of Surgery, University of Oklahoma Health  
18 Sciences Center, Oklahoma City, Oklahoma, USA.

19 <sup>6</sup> Advanced Magnetic Resonance Center, Oklahoma Medical Research Foundation,  
20 Oklahoma City, Oklahoma, USA.

21 <sup>7</sup> Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma  
22 City, Oklahoma, USA.

23

24 **\*Corresponding authors:**

25 Feifan Zhou: zhouff@hainanu.edu.cn

26 Junle Qu: jlqu@szu.edu.cn.


27 Wei R. Chen: Wei-R-Chen@ou.edu.

28

29

30

1 Supplementary Figures




2

3 **Fig. S1.** Fourier transform infrared (FT-IR) spectra of IONs, IMQ@IONs, and IMQ.

4


5

6




7

8 **Fig. S2.** Thermogravimetric analysis (TGA) of IONs, IMQ@IONs, and  
9 IMQ@IONs/ICG under N<sub>2</sub> atmosphere in the temperature range of 25 - 800 °C at a rate  
10 of 10 °C min<sup>-1</sup>.




1  
2  
3  
4  
5  
6  
7  
8  
9

**Fig. S3. Determination of ICG loading on IMQ@IONS/ICG by UV-vis spectra. (A)** Absorption spectra of ICG solution at different concentrations. **(B)** The standard curve of ICG absorption at 790 nm, which was used for determination of the load rate of ICG.




10  
11  
12  
13  
14  
15  
16  
17

**Fig. S4. Hydrodynamic diameter distribution of IMQ@IONS/ICG after being immersed in serum at different time point. Data are expressed as means  $\pm$  SD (n = 3).**




1  
2  
3  
4  
5  
6  
7  
8

**Fig. S5.** Transmission electron microscope (TEM) images of IMQ@IONs/ICG after incubation in (A) pH 7.4 PBS and (B) pH 6.8 PBS for 2 h.




9  
10  
11  
12

**Fig. S6.** Electron spin resonance (ESR) spectra of IMQ@IONs NPs in the presence of  $H_2O_2$  at different pHs. 5-diethoxyphosphoryl-5-methyl-1-pyrroline N-oxide (DEPMPO) was used as the spin trap agent.




1  
2  
3  
4  
5  
6  
7  
8

**Fig. S7.** Cumulative release of IMQ from IMQ@IONs nanoparticles in pH 7.4 PBS buffer and pH 6.8 PBS buffer at room temperature. Data are expressed as means  $\pm$  SD (n = 3).




9  
10  
11  
12

**Fig. S8.** Fluorescence spectra of IMQ@IONs/ICG and ICG under an 805-nm laser excitation.




1  
2  
3  
4  
5  
6

**Fig. S9.** Infrared (IR) thermal images of IMQ@IONs/ICG solution under laser irradiation (805 nm,  $0.75 \text{ W cm}^{-2}$  for 5 min).




7  
8  
9  
10  
11

**Fig. S10.** Representative fluorescence images of Panc02-H7 cells after 2 h incubation with IONs ( $100 \mu\text{g mL}^{-1}$ ), ICG ( $15 \mu\text{g mL}^{-1}$ ), IONs/ICG ( $100 \mu\text{g mL}^{-1}$ ), and IMQ@IONs/ICG ( $100 \mu\text{g mL}^{-1}$ ). Green: ICG, Red: Lyso-tracker, Blue: DAPI. (Scale bar =  $50 \mu\text{m}$ ).




1  
2  
3  
4  
5  
6  
7  
8

**Fig. S11.** Cellular uptake of ICG by Panc02-H7 cells incubation with PBS, IONs (100  $\mu\text{g mL}^{-1}$ ), ICG (15  $\mu\text{g mL}^{-1}$ ), IONs/ICG (100  $\mu\text{g mL}^{-1}$ ), and IMQ@IONs/ICG (100  $\mu\text{g mL}^{-1}$ ), analyzed by flow cytometry.



9  
10  
11  
12  
13  
14  
15

**Fig. S12.** Cytotoxicity of nanoparticles on Panc02-H7 cells with or without laser irradiation. (A) *In vitro* cytotoxicity of IMQ@IONs/ICG on Panc02-H7 cells after incubation for 24 h, analyzed by a CCK-8 assay. (B) *In vitro* phototoxicity of IONs/ICG and IMQ@IONs/ICG on Panc02-H7 cells analyzed by a CCK-8 assay (Laser: 805 nm, 0.75  $\text{W cm}^{-2}$  for 5 min, \*\*\* $p < 0.001$  vs IMQ@IONs). Data are expressed as means  $\pm$  SD (n = 4).



1


2 **Fig. S13.** Representative fluorescence images of Panc02-H7 cells showing  
 3 calreticulin (CRT) exposure on the surface after the treatment with  
 4 IMQ@IONs/ICG, PBS + L, ICG+L, IONs + L, IONs/ICG + L, or  
 5 IMQ@IONs/ICG + L. Green: CRT-FITC, Blue: DAPI. (Laser: 805 nm, 0.75 W  
 6 cm<sup>-2</sup> for 5 min, Scare bar = 50 μm.)

7

8

9


10



11

12 **Fig. S14.** Flow cytometry analysis of CRT exposure on the surface of Panc02-H7 cells  
 13 after the treatment with IMQ@IONs/ICG, PBS, PBS + L, IONs + L, IONs/ICG + L, or  
 14 IMQ@IONs/ICG + L.






1

2 **Fig. S15.** The release of high mobility group 1 (HMGB1) from Panc02-H7 cells after  
 3 the treatment with PBS + L, IONs + L, IONs/ICG + L, or IMQ@IONs/ICG + L (Laser:  
 4 805 nm, 0.75 W cm<sup>-2</sup> for 5 min; \*\*\*p < 0.001 vs PBS + L, one-way ANOVA with  
 5 Tukey test). Data are expressed as means ± SD (n = 4).


6

7




8

9 **Fig. S16.** Representative fluorescence images of Panc02-H7 cells showing HMGB1  
 10 exposure after the treatment with IMQ@IONs/ICG, PBS + L, IONs + L,  
 11 IONs/ICG + L, or IMQ@IONs/ICG + L. Green: HMGB1-FITC, Blue: DAPI.  
 12 (Laser: 805 nm, 0.75 W cm<sup>-2</sup> for 5 min, Scare bar = 50 μm.)




1  
 2 **Fig. S17.** Secretion of TNF- $\alpha$  from BMDCs stimulated by indicated nanoparticles  
 3 (\*\*\*)  $p < 0.001$  vs PBS, one-way ANOVA with Tukey test). Data are expressed as means  
 4  $\pm$  SD (n = 4).

5  
 6  
 7




8  
 9 **Fig. S18.** Tissue distribution of IMQ@IONs/ICG analyzed by *in vivo* fluorescence  
 10 **imaging.** (A) Representative fluorescence images of Panc02-H7 tumor-bearing mice at  
 11 indicated time points (1, 3, 6, and 24 h) after intravenous injection of ICG (40  $\mu$ g mL<sup>-1</sup>,  
 12 100  $\mu$ L) and IMQ@IONs/ICG (10 mg mL<sup>-1</sup>, 100  $\mu$ L). Tumors are circled with black  
 13 dashed lines. (B) Ex vivo fluorescence images of excised organs and tumors at 6 h post  
 14 injection of ICG and IMQ@IONs/ICG. (C) The semi-quantitative analysis of  
 15 fluorescence signals captured from these organs and tumors 6 h post injection.




1

2 **Fig. S19. Tissue distribution of IMQ@IONs/ICG analyzed by MRI.** (A)  
 3 Representative T<sub>2</sub>-weighted MR images of Panc02-H7 tumor-bearing mice at indicated  
 4 time points after intravenous injection of IMQ@IONs/ICG (10 mg mL<sup>-1</sup>, 100 μL).  
 5 Tumors are circled with red dashed lines. Corresponding representative T<sub>1</sub>-weighted  
 6 signals of (B) tumor, (C) liver, (D) kidney, and (E) spleen at different time points after  
 7 intravenous injection of IMQ@IONs/ICG.




8

9 **Fig. S20. Hematology and blood biochemistry analysis of mice *i.v.* injected with**  
 10 **IMQ@IONs/ICG (100 mg/kg) at 15th day.** The examined parameters included: white  
 11 blood cell count (WBC), lymphocyte count (Lymph), monocytes count (Mons),  
 12 neutrophilic granulocyte count (Gran), red blood cell count (RBC), hemoglobin (HGB),  
 13 hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin  
 14 (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell volume  
 15 distribution width (RDW), platelet (PLT), mean platelet volume (MPV), platelet  
 16 distribution width (PDW), thrombocytocrit (PCT). Data are expressed as means ± SD  
 17 (n = 4).




1  
2  
3  
4  
5  
6  
7  
8

**Fig. S21.** Representative H&E-stained images of major organs from the healthy mice after intravenous injection of PBS (100  $\mu\text{L}$ ) or IMQ@IONs/ICG (10  $\text{mg mL}^{-1}$ , 100  $\mu\text{L}$ ). The scale bar = 200  $\mu\text{m}$ .




9  
10  
11  
12  
13  
14  
15  
16

**Fig. S22. Pharmacokinetics of IMQ@FNPs/ICG.** C57BL6 mice were *i.v.* injected with IMQ@FNPs/ICG to study the blood circulation time of IMQ@FNPs/ICG. Blood samples were collected and measured by ICP-OES at various time points post injection (up to 24 hours). The half-life of the IMQ@FNPs/ICG blood circulation was estimated to be  $\sim 41.2$  mins. Data are expressed as means  $\pm$  SD ( $n = 4$ ).



1  
2  
3  
4  
5  
6  
7  
8  
9


**Fig. S23.** Representative T<sub>2</sub>-weighted MR images of mice showing the location of optical fiber in pancreatic tumor during interventional photoimmunotherapy. Tumors are circled with white dashed lines, and red arrows point to the optical fiber.




10  
11  
12  
13  
14  
15  
16  
17

**Fig. S24. IR thermal imaging during IPTT.** (A) Representative photo images of Panc02-H7 tumor-bearing mice treated with interventional photoimmunotherapy. (B) Representative IR thermal images of Panc02-H7 tumor-bearing mice treated with PBS, ICG, and IMQ@IONS/ICG under an 805-nm laser irradiation (1 W for 10 min).






1  
2 **Fig. S25. Systemic immune response analysis after different treatments.** Cytokine  
3 levels of (A) IL-6, (B) IL-12, and (C) IL-10 in sera from mice isolated at 7 days post  
4 different treatments (\* $p < 0.05$  vs PBS, \*\* $p < 0.01$  vs PBS, \*\*\* $p < 0.001$  vs PBS, one-  
5 way ANOVA with Tukey test). Data are expressed as means  $\pm$  SD ( $n = 4$ ).  
6  
7  
8  
9  
10




11  
12 **Fig. S26.** Representative images of tumor section staining of CD8<sup>+</sup> T cells (Red) and  
13 DAPI (Blue) 7 days after different treatments. Scale bar = 100  $\mu$ m.




1  
2  
3  
4  
5

**Fig. S27.** Representative flow plots used to quantify changes in the relative abundance of CD8<sup>+</sup> cell subpopulations in tumors following different treatments.




6  
7  
8  
9  
10

**Fig. S28.** Representative flow plots used to quantify changes in the relative abundance of CD4<sup>+</sup> cell subpopulations in tumors following different treatments.




11  
12  
13  
14  
15

**Fig. S29.** Gating strategy determine frequencies of T cells from tumors. The gating strategy was performed based on exclusion of doublets by FSC-A and FSC-Width, exclusion of dead cells, selection of CD45<sup>+</sup>, and further staining using CD8 and CD4 with appropriate fluorescent dyes to select CD8<sup>+</sup> or CD4<sup>+</sup> T cells, respectively.




1  
2  
3  
4  
5

**Fig. S30.** Representative flow plots used to quantify changes in the relative abundance of T<sub>reg</sub> subpopulations in tumors following different treatments.



6  
7  
8  
9  
10  
11  
12


**Fig. S31.** Gating strategy determine frequencies of T<sub>regs</sub> from tumors. The gating strategy was performed based on exclusion of doublets by FSC-A and FSC-Width, exclusion of dead cells, selection of CD45<sup>+</sup>, selection of CD3<sup>+</sup>, selection of CD4<sup>+</sup>, and further staining using FcγR3 and CD25 with appropriate fluorescent dyes to select T<sub>regs</sub>.



13  
14  
15

**Fig. S32.** Representative flow plots used to quantify changes in the relative abundance of M2-like TAM subpopulations in tumors following different treatments.





1  
2  
3  
4  
5  
6  
7

**Fig. S33. Gating strategy determine frequencies of M2-like TAM from tumors.**  
 The gating strategy was performed based on exclusion of doublets by FSC-A and FSC-Width a), exclusion of dead cells, selection of CD45<sup>+</sup>, selection of CD11b<sup>+</sup>, and further staining using F4/80 and CD206 with appropriate fluorescent dyes to select M2-like TAM cells.

## 1 **Experimental Section**

### 2 **Materials**

3 Fe(CO)<sub>5</sub>, cetyltrimethylammonium bromide (CTAB, >99%), indocyanine green  
4 (ICG, >90%), imiquimod (IMQ), H<sub>2</sub>O<sub>2</sub> (30%), methanol, ethanol, 1-hexanol, n-  
5 dodecane, and diethylene glycol (DEG) were purchased from Sigma-Aldrich (St Louis,  
6 MO). DSPE-PEG (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-  
7 N[methoxy(polyethylene glycol)]) with the PEG molecular weight 2000 (DSPE-  
8 PEG<sub>2k</sub>) was obtained from Avanti Polar Lipids (Alabaster, AL). Dulbecco's modified  
9 Eagle's medium (DMEM), Roswell Park Memorial Institute (RPMI) 1640 medium,  
10 fetal bovine serum (FBS), 0.25% trypsin-EDTA, penicillin, and streptomycin were  
11 purchased from Gibco (Grand Island, NY).

### 12 **Cell Line**

13 Panc02-H7, an aggressive pancreatic cell line, was derived from Panc02 that was  
14 established by implanting 3-methylcholanthrene into the pancreas of a C57BL/6 mouse.  
15 Panc02-H7 cells were tested and verified to be free of Mycoplasma and used after two  
16 passages from thawing. The cells were cultured with DMEM, supplemented with 10%  
17 FBS, penicillin (100 U mL<sup>-1</sup>), and streptomycin (100 mg mL<sup>-1</sup>), in a humidified  
18 incubator with 5% CO<sub>2</sub>, 95% air at 37 °C (NuAire).

### 19 **Characterization of Nanoparticles**

20 TEM images were obtained via JEOL-2010 TEM (JEOL, Japan). The amounts of  
21 loaded ICG and IMQ were quantitatively evaluated via UV-vis-NIR  
22 spectrophotometer (Cary 50 Bio, USA). The loading capacity of ICG was calculated

1 using the following equation: loading capacity of ICG (%) = (weight of ICG - weight  
2 of unloaded ICG) / (weight of IMQ@IONs/ICG) × 100%. The loading capacity of IMQ  
3 was calculated using the following equation: loading capacity of IMQ (%) = (weight of  
4 loaded IMQ) / (weight of IMQ@IONs/ICG) × 100%. Fourier transform infrared (FTIR)  
5 spectra were recorded in KBr discs on a Magna 750 FTIR spectrometer. The  
6 hydrodynamic diameter distribution of nanoparticles was determined by means of  
7 dynamic light scattering (DLS) measurement (Nano ZS ZEN3600, Malvern).

### 8 **Thermal Stability of IMQ@IONs/ICG**

9 IMQ@IONs/ICG aqueous solution (0.5 mg mL<sup>-1</sup> in 0.3 mL) was irradiated with  
10 an 805 nm laser at 0.75 W cm<sup>-2</sup> for 5 min, and then naturally cooled to room temperature.  
11 The above process was repeated three times.

### 12 **Calculation of the photothermal conversion efficiency of IMQ@IONs/ICG**

13 The photothermal conversion efficiency of IMQ@IONs/ICG was determined  
14 according to a previously reported method as follows Equation [1].

$$15 \quad \eta = \frac{hA\Delta T - Q_s}{I(1 - 10^{-A_\lambda})}$$

16 Where  $h$  is the coefficient of heat transfer,  $A$  is the container surface area,  $\Delta T$  is  
17 the temperature change of the IMQ@IONs/ICG solution,  $I$  is the power density of the  
18 805 nm laser,  $A_\lambda$  is the absorbance of the solution of IMQ@IONs/ICG at 805 nm, and  
19  $Q_s$  is the heat associated with the light absorbance of the water.

### 20 **Cytotoxicity and Apoptosis Assay**

1 For cell viability analysis, Panc02-H7 cells were seeded into 96-well plates at a  
2 density of  $1 \times 10^3$  cells per well and cultured for 12 h. The cells were treated with ICG,  
3 IONs, and IMQ@IONs/ICG at various concentrations. After incubation for 2 h, the  
4 cells were irradiated with or without an 805 nm laser ( $0.75 \text{ W cm}^{-2}$  for 5 min). The cells  
5 were further incubated for 24 h and cell viability was detected via CCK-8 assay,  
6 according to the manufacturer's protocol. In addition, treated Panc02-H7 cells were  
7 stained with Calcein AM and PI and observed with confocal microscopy, to verify the  
8 cell death.

9 Apoptosis of tumor cells was assessed by Annexin V-FITC/PI Cell Apoptosis Kit.  
10 Cells were seeded into 12-well plates ( $5 \times 10^5$  cells/well) and cultured for 12 h. Cells  
11 were treated with PBS, ICG, IONs, and IMQ@IONs/ICG at an equivalent ICG  
12 concentration ( $30 \mu\text{g mL}^{-1}$ ). After 2 h of incubation, the cells were irradiated with an  
13 805 nm laser ( $0.75 \text{ W cm}^{-2}$  for 5 min), followed by a further 24 h incubation.  
14 IMQ@IONs/ICG without laser irradiation served as the dark control. The cell apoptosis  
15 was detected by flow cytometry with Annexin V-FITC/PI staining, according to the  
16 manufacturer's protocol.

### 17 **Detection of ICD Biomarkers**

18 Surface-exposure of CRT on Panc02-H7 cells was assessed *via* flow cytometry  
19 and immunofluorescence. Cells were seeded into 8-well chambered slides and cultured  
20 for 12 h. The cells were incubated with PBS, IONs, or IMQ@IONs/ICG for 2 h and  
21 irradiated with an 805 nm laser ( $0.75 \text{ W cm}^{-2}$  for 5 min). Cells treated with  
22 IMQ@IONs/ICG without laser irradiation served as dark control. After a further 24 h

1 of incubation, cells were washed twice with PBS and then incubated with anti-  
2 calreticulin antibody for 2 h at 4 °C. Subsequently, the cells were washed twice with  
3 PBS and incubated with PE-conjugated secondary antibody (BioLegend, USA) for 1 h.  
4 The samples were analyzed by flow cytometer to identify cell surface CRT. For  
5 immunofluorescence analysis, the treated cells were further stained with DAPI, and  
6 observed *via* fluorescence microscopy (Olympus, Japan). Extracellular HMGB1 in  
7 conditioned media (serum-free) secreted from treated cells were measured *via* HMGB1  
8 ELISA Kit (R&D systems), following the manufacturer's instructions.

### 9 **In Vitro Dendritic Cell Stimulation**

10 Bone marrow–derived dendritic cells (BMDCs) were generated from 8 weeks old  
11 C57BL/6 female mice, according to an established method [2]. For *in vitro* DC  
12 stimulation experiments, ICG, IONs or IMQ@IONs/ICG were incubated with 10<sup>6</sup>  
13 BMDCs for 24 h. After various treatments, BMDCs stained with anti-CD86-PE and  
14 anti-CD80-FITC antibody were analyzed via Stratedigm S1200Ex flow cytometer  
15 (Stratedigm, USA).

### 16 **Multimodal Imaging**

17 Tumor bearing mice were randomly divided into two groups. About 7-10 days  
18 after tumor inoculation, when the pancreatic tumors reached a size of 8 mm  
19 (approximately 300 mm<sup>3</sup>) in diameter, mice were injected with ICG or  
20 IMQ@IONs/ICG by *i.v.* The FL signals of ICG were recorded with an IVIS spectrum  
21 imaging system (Xenogen, USA) (ex: 780 nm) at 1, 4, and 24 h. The FL images of mice  
22 before injection served as blank control. For the biodistribution study, mice were

1 sacrificed 24 h post injection, and both tumors and normal tissues were harvested and  
2 imaged. Similarly, MR images of the tumor sites were recorded with a 7.1 Tesla MR  
3 scanner (Bruker Biospin, USA) at pre, 0.5, 1, 1.5, 2, 3, 4 and 7 h. The MR images of  
4 mice before injection served as blank control.

### 5 **MR temperature imaging and PRF-shift calculation**

6 The temperature shift during interventional photothermal therapy was assessed  
7 using proton resonance frequency (PRF)-shift thermometry. Since the PRF-shift  
8 method had better temperature sensitivity, excellent linearity and near-independence  
9 with tissue type, it was the preferred choice for temperature MRI mapping. According  
10 to the Larmor equation, the phase obtained within a voxel at a temperature T was given  
11 as follows:

$$12 \quad \varphi(T) = \gamma TE [(1 - \sigma_{tot}(T))B_0 + \delta B_0]$$

13 Among them,  $\varphi(T)$  was the phase at a temperature T,  $\gamma$  was the gyromagnetic ratio  
14 of hydrogen ( $\gamma/2\pi = 42.577 \times 10^6 \text{ s}^{-1} \text{ T}^{-1}$ ), TE was the echo time,  $\sigma_{tot}(T)$  was the total  
15 screening constant of the proton,  $B_0$  was the main magnetic field of the MRI scanner  
16 and  $\delta B_0$  was the local deviations from  $B_0$ .

17 When the temperature changed from T to T', the phase difference ( $\Delta\varphi$ ) was  
18 measured in a voxel.

$$19 \quad \Delta\varphi = \varphi(T') - \varphi(T) = \gamma TE (\sigma_{tot}(T) - \sigma_{tot}(T')) B_0 = -\gamma TE \alpha \Delta T B_0$$

20 Here,  $\Delta T$  was the temperature difference between T' and T, and  $\alpha$  was a  
21 proportionality constant in the linear temperature dependence of  $\sigma_{tot}$ .

22 The tumor-bearing mice were imaged under an external magnetic field of  $B_0 = 7.0$

1 T and with an echo time of  $TE = 4$  ms. The phase shift between successive images was  
2 calculated using the formula given in equation:

$$3 \quad \Delta\varphi = \varphi_n - \varphi_0 = \arctan\left(\frac{\Re(T_0)\Im(T_n) - \Re(T_n)\Im(T_0)}{\Re(T_0)\Re(T_n) + \Im(T_0)\Im(T_n)}\right)$$

4 where  $\Re(T_n)$  refers to the real part of the  $n^{\text{th}}$  image,  $\Im(T_n)$  refers to the imaginary  
5 part of the  $n^{\text{th}}$  image, and  $T_0$  refers to the image captured at the start of laser treatment.

6 Then, the temperature shift can be calculated according to equation:

$$7 \quad \Delta T = \frac{\Delta\varphi}{\alpha\gamma T E B_0}$$

### 8 **Phase-drift correction and post-processing**

9 Phase-drift was calculated for each 2D tomogram by finding the best fit first-order  
10 polynomial to the region of the data outside of the heating area. To determine the  
11 appropriate region of interest, a mask was generated by maximizing the contrast about  
12 the point 0.2 in magnitude which was qualitatively determined from histograms of the  
13 data to primarily exclude points in the MRI image outside of the animal tissue. The  
14 opening of the region of interest by a disc structural element with a radius of 5 pixels  
15 was then calculated to remove clean up the edges of the mask. The internal heating  
16 region of interest was determined by the union of the external region of interest with a  
17 mask generated from maximizing the contrast about the point -0.2 radians phase-shift  
18 which was qualitatively determined to denote the heating region. The internal region of  
19 interest was then opened with a disc structural element with a radius of 10 pixels and  
20 then dilated with a disc structural element with a radius of 5 pixels. The dilated internal  
21 region of interest was then clipped to the external region of interest and then subtracted

1 out from the external region of interest.

2 The phase-drift  $\Delta\varphi_d$  can be thought of as the phase-shift within the external region  
3 of interest. As such, the phase shift within the external region of interest was fit to a  
4 first-order polynomial  $\Delta\varphi_d = a_0 + a_x X + a_y Y$  where  $a_0$  is the zeroth-order  
5 coefficient and  $a_x$  and  $a_y$  are the first-order coefficients along the X and Y dimensions,  
6 respectively. The phase-drift was then subtracted out from the phase-shift data, and the  
7 internal region of interest was re-calculated as above to serve as a mask for the  
8 temperature data.

## 9 **Immunofluorescence Assay**

10 Tumors were collected and frozen tissue sections of 6  $\mu\text{m}$  thickness were prepared  
11 via cryostat. These sections were air-dried for at least 1 h and then fixed in acetone for  
12 10 min at room temperature. After blocking with 20% donkey serum, the sections were  
13 incubated with antibodies, washed twice with PBS, and observed via fluorescence  
14 microscopy (Olympus, Japan).

15

## 16 **References**

17 [1] B. Li, Q. Wang, R. Zou, X. Liu, K. Xu, W. Li, J. Hu, Cu<sub>7</sub>.2S<sub>4</sub> nanocrystals: a novel  
18 photothermal agent with a 56.7% photothermal conversion efficiency for  
19 photothermal therapy of cancer cells, *Nanoscale* 6(6) (2014) 3274-3282.

20 [2] J. Helft, J. Böttcher, P. Chakravarty, S. Zelenay, J. Huotari, Barbara U. Schraml, D.  
21 Goubau, C. Reis e Sousa, GM-CSF Mouse Bone Marrow Cultures Comprise a  
22 Heterogeneous Population of CD11c<sup>+</sup>MHCII<sup>+</sup> Macrophages and Dendritic Cells,



1 Immunity 42(6) (2015) 1197-1211.

2